ArticleScientific reports2025
A retrospective analysis of systolic blood pressure time in target range among patients in coronary care unit.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The research aimed to illustrate the prognostic value of systolic blood pressure time in target range (SBP-TTR) calculated by continuously monitoring blood pressure (BP) records among patients admitted to coronary care units. Data from the Medical Information Mart for Intensive Care-IV database was used in this retrospective cohort study. Systolic blood pressure (SBP) target ranges were defined as 110-140 mmHg for awake time, and 90-120 mmHg for sleep time, respectively. SBP-TTR was calculated as the proportion of measured SBP in the target range among all SBP measurements, and participants were divided into four groups according to the categories of TTR. We used Cox proportional hazard regression models to assess the association between SBP-TTR and one-year all-cause mortality. A total of 4665 patients with 394,267 BP records were included in the study. During a maximum of 365 follow-up days, the cumulative incidence of all-cause death diminished with the increase of TTR categories. After multivariable adjustment, comparing with the lowest category, the highest category of SBP-TTR showed significantly decreased risk on one-year mortality (HR:0.50, 95%CI 0.36-0.71, P < 0.0001), and 10% increment of TTR was associated with 12% decrease of all-cause mortality (HR:0.88, 95%CI 0.85-0.91, P < 0.0001). In sensitivity analyses, both awake and sleep SBP targets were reset to wider ranges, and the results remained robust. Subgroup analyses generated consistent results across different demographic characteristics, baseline BP levels and comorbidities. There was a negative association between SBP-TTR and one-year all-cause mortality in CCU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.